Myriad Genetics, Inc. (NASDAQ:MYGN) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other equities analysts also recently issued reports on MYGN. TheStreet raised shares of Myriad Genetics from a “d+” rating to a “c” rating in a report on Wednesday, March 1st. Stephens raised shares of Myriad Genetics from an “equal weight” rating to an “overweight” rating and set a $20.00 price target for the company in a report on Monday, March 13th. Jefferies Group LLC reissued a “hold” rating and set a $18.00 price target on shares of Myriad Genetics in a report on Friday, March 24th. Cowen and Company reissued a “market perform” rating and set a $19.00 price target on shares of Myriad Genetics in a report on Tuesday, March 28th. Finally, Deutsche Bank AG lifted their price target on shares of Myriad Genetics from $15.00 to $20.00 and gave the company a “sell” rating in a report on Monday, May 8th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. Myriad Genetics has a consensus rating of “Hold” and a consensus target price of $23.00.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ MYGN) traded up 2.09% during midday trading on Friday, reaching $23.88. 1,955,957 shares of the company traded hands. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of 51.03 and a beta of 0.34. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $32.97. The firm’s 50 day moving average price is $21.44 and its 200 day moving average price is $18.67.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, May 2nd. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.03. Myriad Genetics had a net margin of 2.13% and a return on equity of 2.27%. The firm had revenue of $196.90 million during the quarter, compared to the consensus estimate of $188.89 million. On average, analysts expect that Myriad Genetics will post $1.01 earnings per share for the current year.

WARNING: “Myriad Genetics, Inc. (MYGN) Upgraded at BidaskClub” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/17/myriad-genetics-inc-mygn-upgraded-at-bidaskclub.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. boosted its position in shares of Myriad Genetics by 168,335.7% in the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock worth $183,203,000 after buying an additional 9,536,219 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Myriad Genetics by 16.8% in the first quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock worth $120,020,000 after buying an additional 897,287 shares in the last quarter. Camber Capital Management LLC boosted its position in shares of Myriad Genetics by 6.5% in the first quarter. Camber Capital Management LLC now owns 4,325,000 shares of the company’s stock worth $83,040,000 after buying an additional 265,000 shares in the last quarter. State Street Corp boosted its position in shares of Myriad Genetics by 15.8% in the fourth quarter. State Street Corp now owns 3,589,079 shares of the company’s stock worth $59,836,000 after buying an additional 488,484 shares in the last quarter. Finally, Frontier Capital Management Co. LLC boosted its position in shares of Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock worth $59,058,000 after buying an additional 41,432 shares in the last quarter.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.